Cellebrite DI Statistics
Total Valuation
Cellebrite DI has a market cap or net worth of $3.32 billion. The enterprise value is $2.83 billion.
Important Dates
The next confirmed earnings date is Thursday, August 14, 2025, before market open.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellebrite DI has 239.47 million shares outstanding. The number of shares has increased by 13.90% in one year.
| Current Share Class | 239.47M |
| Shares Outstanding | 239.47M |
| Shares Change (YoY) | +13.90% |
| Shares Change (QoQ) | +0.79% |
| Owned by Insiders (%) | 2.71% |
| Owned by Institutions (%) | 37.26% |
| Float | 107.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 29.39 |
| PS Ratio | 7.29 |
| Forward PS | 6.56 |
| PB Ratio | 9.08 |
| P/TBV Ratio | 10.29 |
| P/FCF Ratio | 24.93 |
| P/OCF Ratio | 23.29 |
| PEG Ratio | 1.89 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 40.18, with an EV/FCF ratio of 21.20.
| EV / Earnings | n/a |
| EV / Sales | 6.76 |
| EV / EBITDA | 40.18 |
| EV / EBIT | 47.25 |
| EV / FCF | 21.20 |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.82 |
| Quick Ratio | 1.70 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | 0.08 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -115.35% and return on invested capital (ROIC) is 20.79%.
| Return on Equity (ROE) | -115.35% |
| Return on Assets (ROA) | 6.05% |
| Return on Invested Capital (ROIC) | 20.79% |
| Return on Capital Employed (ROCE) | 14.20% |
| Revenue Per Employee | $359,186 |
| Profits Per Employee | -$166,440 |
| Employee Count | 1,167 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 7.33 |
Taxes
In the past 12 months, Cellebrite DI has paid $6.91 million in taxes.
| Income Tax | 6.91M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.66% in the last 52 weeks. The beta is 1.27, so Cellebrite DI's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | +2.66% |
| 50-Day Moving Average | 15.13 |
| 200-Day Moving Average | 18.74 |
| Relative Strength Index (RSI) | 40.91 |
| Average Volume (20 Days) | 1,523,316 |
Short Selling Information
The latest short interest is 3.63 million, so 1.52% of the outstanding shares have been sold short.
| Short Interest | 3.63M |
| Short Previous Month | 3.36M |
| Short % of Shares Out | 1.52% |
| Short % of Float | 3.38% |
| Short Ratio (days to cover) | 2.40 |
Income Statement
In the last 12 months, Cellebrite DI had revenue of $419.17 million and -$194.24 million in losses. Loss per share was -$0.89.
| Revenue | 419.17M |
| Gross Profit | 352.35M |
| Operating Income | 59.93M |
| Pretax Income | -106.25M |
| Net Income | -194.24M |
| EBITDA | 70.49M |
| EBIT | 59.93M |
| Loss Per Share | -$0.89 |
Full Income StatementBalance Sheet
The company has $409.49 million in cash and $10.60 million in debt, giving a net cash position of $499.19 million or $2.08 per share.
| Cash & Cash Equivalents | 409.49M |
| Total Debt | 10.60M |
| Net Cash | 499.19M |
| Net Cash Per Share | $2.08 |
| Equity (Book Value) | 363.49M |
| Book Value Per Share | 1.53 |
| Working Capital | 235.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $143.01 million and capital expenditures -$9.41 million, giving a free cash flow of $133.60 million.
| Operating Cash Flow | 143.01M |
| Capital Expenditures | -9.41M |
| Free Cash Flow | 133.60M |
| FCF Per Share | $0.56 |
Full Cash Flow StatementMargins
Gross margin is 84.06%, with operating and profit margins of 14.30% and -46.34%.
| Gross Margin | 84.06% |
| Operating Margin | 14.30% |
| Pretax Margin | -44.69% |
| Profit Margin | -46.34% |
| EBITDA Margin | 16.82% |
| EBIT Margin | 14.30% |
| FCF Margin | 31.87% |
Dividends & Yields
Cellebrite DI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.90% |
| Shareholder Yield | -13.90% |
| Earnings Yield | -5.83% |
| FCF Yield | 4.01% |
Dividend DetailsAnalyst Forecast
The average price target for Cellebrite DI is $22.43, which is 61.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.43 |
| Price Target Difference | 61.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 15.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellebrite DI has an Altman Z-Score of 7.13 and a Piotroski F-Score of 4.
| Altman Z-Score | 7.13 |
| Piotroski F-Score | 4 |
